In vivo real-time epifluorescence imaging of mouse hind limb vasculatures in the second near-infrared region (NIR-II) is performed using single-walled carbon nanotubes as fluorophores. Both high spatial (~30 mm) and temporal (<200 ms per frame) resolution for small-vessel imaging are achieved at 1-3 mm deep in the hind limb owing to the beneficial NIR-II optical window that affords deep anatomical penetration and low scattering. This spatial resolution is unattainable by traditional NIR imaging (NIR-I) or microscopic computed tomography, and the temporal resolution far exceeds scanning microscopic imaging techniques. Arterial and venous vessels are unambiguously differentiated using a dynamic contrast-enhanced NIR-II imaging technique on the basis of their distinct hemodynamics. Further, the deep tissue penetration and high spatial and temporal resolution of NIR-II imaging allow for precise quantifications of blood velocity in both normal and ischemic femoral arteries, which are beyond the capabilities of ultrasonography at lower blood velocities.
Development of new therapies for peripheral arterial diseases (PADs) may be facilitated by imaging that provides anatomic and hemodynamic information with high spatial and temporal resolu tion. However, current methods for assessing vasculature and hemo dynamics in small vessels in vivo are suboptimal 1 . For imaging vascular structures, microscopic computed tomography (microCT) and magnetic resonance imaging (MRI) can resolve features down to ~100 µm with deep penetration but are limited by long scanning and postprocessing times, and difficulties in assessing vascular hemody namics 2, 3 . Vascular hemodynamics are usually obtained by Doppler measurements of microultrasonography with high temporal resolu tion of up to 1,000 Hz, but spatial resolution attenuates with increased depth of penetration 4 .
In vivo fluorescencebased optical imaging has inherent advantages over tomographic imaging owing to high temporal and spatial resolu tion 5, 6 . Singlewalled carbon nanotubes (SWNTs), nanoscale cylin ders of rolledup graphite sheets composed of carbon, are an emerging nanomaterial with unique optical properties for in vivo anatomical imaging 7, 8 , tumor detection 9, 10 and photothermal treatment [10] [11] [12] .
One unique feature of SWNTs is their intrinsic fluorescence in the second nearinfrared window (NIRII, 1.1-1.4 µm) upon excitation in the traditional nearinfrared region (NIRI, 0.75-0.9 µm), with large Stokes shift up to ~400 nm. Compared to the NIRI window, which has been extensively explored for in vitro and in vivo imaging [13] [14] [15] [16] [17] [18] , the longer wavelength emission in NIRII makes SWNTs advantageous for imaging owing to reduced photon absorption 19, 20 , reduced scatter ing by tissues 8, 21 , negligible tissue autofluorescence and, thus, deeper tissue penetration 7, 8, 22 . This allows for unprecedented fluorescence based imaging resolution of anatomical features deep to the skin.
Here we report the use of biocompatible, brightly fluorescent SWNTs as NIRII imaging agents for imaging vascular structures down to ~30 µm in mouse hind limb using an epifluorescence imag ing method with an indiumgalliumarsenide (InGaAs) imaging sys tem. Compared to microCT, NIRII fluorescence imaging attains an ~3fold improvement in spatial resolution. Further, NIRII imaging allows for differentiation of arteries from veins through principal component analysis (PCA) 8, 23 to obtain dynamic contrastenhanced imaging. We can also quantify femoral artery blood flows in both normal and ischemic hind limbs and reveal the degree of occlusion due to ischemia. Thus, a single NIRII imaging modality enables mul tifunctional imaging capable of accomplishing what is typically done by several traditional techniques, including microCT, ultrasonogra phy and MRI, and incorporates many desirable features such as high spatial resolution (~30 µm), fast acquisition (<200 ms), good tissue penetration (1-3 mm), vessel specification and blood flow quantifica tion for hind limb vessel imaging.
RESULTS

NIR-I and NIR-II fluorescence imaging of vasculatures
First, to glean the differences between in vivo NIRI and NIRII fluores cence imaging, we made biocompatible SWNTIRDye800 conjugates as dualcolor imaging agents, where IRDye800 is a commercial NIRI fluorophore. Highpressure carbon monoxide conversion SWNTs were stably suspended by biocompatible surfactants of 75% DSPEmPEG (1,2distearoylsnglycero3phosphoethanolamineN [methoxy(pol yethyleneglycol)], 5 kDa) and 25% DSPEPEGNH 2 (1,2distearoyl snglycero3phosphoethanolamineN[amino(polyethyleneglycol) 
Multifunctional in vivo vascular imaging using near-infrared II fluorescence T e c h n i c a l R e p o R T s 1 8 4 2 VOLUME 18 | NUMBER 12 | DECEMBER 2012 naTuRe medicine 5 kDa) with amine groups covalently functionalized with IRDye800 ( Fig. 1a and Supplementary Fig. 1a-c) . Both the SWNT and IRDye 800 label could be excited by a 785 nm laser, but they had different emissions. The IRDye800 dye emitted at ~800 nm in the NIRI, whereas the SWNT emitted in the 1.1-1.4 µm NIRII region (Fig. 1b) .
The dualcolor emission of SWNT-IRDye800 conjugate ensured colocalization of SWNTs and IRDye800 dyes, and enabled us to image the same tissue in two distinct spectral windows so as to evalu ate photons in different wavelengths for live animal imaging. For parenteral administration and live animal imaging, we prepared and intravenously injected a solution (200 µl) of 0.10 mg ml −1 (1.0 mg per kg body weight) SWNTIRDye800 conjugates (Fig. 1c) into a nude mouse. We estimated the maximum SWNT concentration in the blood would be 17 times lower than the halfmaximal inhibitory concentration (IC 50 ) of vascular endothelial cells ( Supplementary  Fig. 1d ). The circulation halftime of DSPEmPEG-functionalized SWNTs was ~5 h (ref. 8) , and our previous studies had shown the lack of acute or longterm toxicity of such PEGylated SWNTs in vivo 10, 24, 25 . The mouse was illuminated using a 785nm laser at 8 mW cm −2 ( Fig. 1d) and imaged in the NIRI (Fig. 1e-g ) using a siliconbased CCD camera and in the NIRII (Fig. 1h-j) using an InGaAs camera equipped with different emission filters. An adjust able lens set was used to obtain three different magnifications: ×1 (whole body), ×2.5 (entire hind limb) and ×7 (partial hind limb).
We found that all images in the NIRI region employing IRDye800 fluorescence showed indistinct vascular anatomy. The corresponding crosssectional intensity profiles were characterized by broad peaks (Fig. 1e-g, bottom) . Presumably, these characteristics were related to substantial scattering and absorbance of NIRI photons, which limited the depth and resolution of traditional NIR imaging in vivo 8 . In contrast, when the same mouse was imaged in the NIRII region by detecting SWNT fluorescence, there was a substantially improved spatial resolution of vessels at all magnifications. Moreover, the NIRII window clearly visualized smaller, higherorder branches of blood vessels at higher magnifications. Crosssectional intensity profiles all showed sharp peaks, with the calculated vessel diameter values consistent with expected values (Fig. 1h-j, bottom) . In contrast, it was impossible to calculate vessel diameters on the basis of the NIRI images, in which we observed an approximately two to threefold broadening of the crosssectional profiles on average.
NIR-II and micro-CT for vessel imaging
MicroCT is a commonly used threedimensional Xray imaging tech nique based on tomographic reconstruction, with a spatial resolution down to ~100 µm and excellent penetration depth 26, 27 . Accordingly, we compared the spatial resolution of the proximal femoral artery and vein achieved by NIRII and microCT methods in the same mouse (Fig. 2a,b) . We performed a crosssectional analysis across the blood vessels in each image, and the corresponding intensity profiles are shown for NIRII (Fig. 2c) and microCT (Fig. 2d) . We identi fied two peaks corresponding to femoral artery and vein in each plot and fitted them into two Gaussian functions to extract the widths. To compare the resolution limits between NIRII and microCT, we determined the smallest vessels these two techniques were able to discern. In the distal hind limb of the mouse, the NIRII image showed greater numbers of small vessels compared to the micro CT image at the same location (Fig. 2e,f) . The smallest measurable vessel by NIRII had a Gaussianfit diameter of only 35.4 µm (Fig. 2g) , whereas microCT could not discern any vessel smaller than ~100 µm in diameter (Fig. 2h) . Furthermore, the NIRII method generated images much faster than microCT (300 ms for NIRII and 2 h for microCT).
Differentiation of arterial and venous vessels
To determine whether NIRII fluorescence imaging could distinguish arterial from venous circulation, we monitored the blood flow inside the vessels by recording movies in the NIRII window immediately upon tailvein injection of SWNT fluorophores. To enable greater temporal resolution (that is, shorter exposure time) for dynamic recordings, we used an 808nm laser at 140 mW cm −2 for more effi cient excitation of SWNT fluorophores.
When we injected a 200µl solution containing 0.10 mg ml −1 bio compatible SWNTs into the tail vein of a nude mouse (mouse C1), we observed a NIRII signal from the SWNTs in the proximal femoral artery within 5 s and the entire femoral artery and some of the proximal musculature after ~8 s (Fig. 3a,b) . Outflow of SWNTs into the femoral vein was reflected by the increased feature width (vascular bundle in the femoral sheath) at later time points but was difficult to distinguish from the femoral artery by visual inspection due to the proximity of the artery and the vein (Fig. 3c) . However, owing to the time delay between the first appearance of the signal in the artery and its later appearance in the vein (Supplementary Movie 1), it was possible to employ PCA to differentiate the two types of vessels 8, 23 . Essentially, the PCA approach assigns image pixels to groups (components) on the basis of their variance, that is, pixels that vary similarly in time.
We applied PCA to the videorate images and clearly discriminated the arterial component from the venous component. By convention, we colorcoded the arterial PCA component in red and the venous component in blue (Fig. 3d) . We obtained similar results with an additional three mice ( Supplementary Fig. 2a-f) .
We repeated these studies in mice after surgically inducing uni lateral hind limb ischemia (mice I1-I3). In this model, ligation and excision of the proximal superficial femoral artery and ligation of the deep femoral artery reduced limb perfusion by ~80% in the immedi ate postoperative period 28 . On the first postoperative day, we studied mice with SWNTassisted NIRII fluorescence imaging. After tail vein injection of SWNTs, we observed a marked delay in the appearance of fluorescent signals in ischemic limbs ( Fig. 3e-g ) compared to healthy limbs. As in normal mice, we performed PCA on the first 200 frames (~37. we did not observe venous return in the ischemic limb at this time point (Fig. 3h and Supplementary Fig. 2g-j) . It was necessary to con tinue imaging for an extended period (>2 min) to visualize the femo ral vein (Supplementary Fig. 3 and Supplementary Movie 3) . This delay in venous return was consistent with severe limb ischemia.
We also applied the dynamic contrast PCA approach to demonstrate that arteries and veins subserving a larger region of tissue could be distinguished. In these studies, we imaged a larger field of view includ ing both the abdominal and femoral regions. Within 5 s of tail vein injection (Supplementary Movie 4) , we observed signals in the aorta as well as the iliac, femoral and epigastric arteries and their branches in the abdomen and pelvis (Fig. 4a,b) . The NIRII signal from these ves sels peaked and then subsided by ~10 s after injection with increasing intensity in the tissue (Fig. 4c) . Subsequently, we observed signals in veins draining these regions, including the previously identified femo ral vein and inferior epigastric veins (Fig. 4d) . As before, we used PCA to assign pixels to arterial or venous conduits on the basis of their time variance (Fig. 4e) , where arteries and veins were resolved. Notably, even the aorta can be seen in supine position of the mouse, indicating a penetration depth of >5 mm in the abdomen for NIRII imaging (Fig. 4f) . This result confirmed the capacity of NIRII dynamic contrastenhanced imaging to distinguish arteries from veins.
Blood flow quantification in ischemic and control limbs NIRII imaging revealed a marked delay in the appearance of fluo rescence signal in ischemic hind limbs versus control healthy limbs. We then assessed blood flow in the ischemic hind limb of mouse I1 quantitatively. From 12 s to 19.5 s after injection of SWNTs, propaga tion of the signal could be visualized from the proximal site of arterial occlusion to the distal femoral artery (Fig. 5a) , presumably filling through collateral channels. The position of the signal front at each time point was then extracted from each frame and plotted against time, showing a linear relationship of flow distance versus time with a blood velocity of 0.163 cm s −1 (Fig. 5b) . To calculate blood flow, we measured the mean diameter of the femoral artery (174 µm). The measurement of blood flow velocity and arterial diameter permitted the calculation of femoral artery blood flow (2.33 × 10 −3 ml min −1 ).
We found the progression of NIRII signal through the femoral artery in normal mice was so rapid that our current video imaging rate lacked sufficient temporal resolution. Alternatively, to assess blood velocity in these mice, we measured the increase in signal intensity in a region of interest (ROI) (a predefined segment of the femoral artery from PCA). We normalized the signal intensity to compensate for differences in actual injected dose or fluorescence quantum yield and plotted the average ROI intensity versus time (see Online Methods). In the mouse with hind limb ischemia, we observed a NIRII inten sity increase of 2.18% s −1 (Fig. 5c) . We then plotted blood flow and NIRII intensity against each other (Fig. 5d) to yield a linear slope of ~0.0737 cm % −1 that correlated velocity with intensity change. We used this coefficient to convert the NIRII intensity increase rate to blood velocity in the normal mice where blood velocity exceeded the temporal resolution of our current imaging device. To further establish this translation coefficient, we reproduced the blood velocity quantification with two other ischemic mice, I2 and I3, and obtained an average value of 0.0747 ± 0.0019 cm % −1 ( Supplementary Fig. 4 and Supplementary Table 1) .
The intensitytovelocity conversion coefficient was applied to measurements of femoral artery blood flow in a healthy, control mouse where the blood velocity was so rapid that our current NIRII imaging device was unable to track a discrete flow front over time (Fig. 5e) . Alternatively, we measured the NIRII intensity change in an ROI of the femoral artery as a function of time (Fig. 5f) , revealing a normalized NIRII intensity increase of 68.7 ± 5.2% s −1 before it peaked. By using the conversion coefficient of 0.0747 cm % −1 , we were able to translate the intensity increase to a blood velocity of 5.13 ± 0.39 cm s −1 . To validate this measure of blood velocity, we used ultrasonography to obtain a Dopplerderived velocity in the same mouse at the same ROI of the femoral artery by an operator blinded to the SWNT imaging values. In the same animal, the ultrasound measurement provided a Dopplerderived velocity of 4.97 ± 0.17 cm s −1 (Fig. 5g) , which was in good agreement with the NIRII video imaging result (a deviation of ~3%).
To further validate our intensitytovelocity conversion coefficient and to understand the physics behind it, we used a simplified fluid dynamic system, in which SWNT solution was pumped into cath eter tubing filled with purified water (Supplementary Fig. 5k) , and derived the coefficient on the basis of NIRII intensity increase (see Online Methods). By changing the experimental settings one at a time, we found the coefficient remained invariant (0.0764 ± 0.0025 cm % −1 ) as we varied the injected SWNT concentration, SWNT fluorescence quantum yield, tubing diameter, ROI length and velocity. It did vary with the distance between the injection site and ROI (preROI length) (Supplementary Fig. 5a-j and Supplementary Table 2 ). This find ing was also confirmed by numerical simulations ( Supplementary  Fig. 5l-s and Supplementary Table 2 ) based on a linear flow model with axial mixing 29 . In the context of in vivo blood velocity quantifica tion, because the preROI length simply reflects the length of blood vessels in which the injected SWNTs had to travel before reaching the femoral artery, the coefficient should be invariant given the same type of animals with roughly same blood volume and therefore applicable from ischemic to control mice.
To demonstrate the reproducibility of the NIRII fluorescencebased blood velocity quantification, we compared the Doppler derived velocities to those of the NIRII method in three additional control mice (Supplementary Fig. 6 ). A summarized plot suggested excellent agreement of results between the two methods (Fig. 5h) . Subsequently, we performed these studies in three ischemic mice. 
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The marked reduction in blood velocity in ischemic limbs (Fig. 5i ) measured by NIRII method was consistent with previous reports 28, 30, 31 . It was noteworthy that blood velocity in the ischemic mice was low and beyond the detection capability of ultrasonography. Clearly, the NIRII imaging technique proved advantageous over ultrasound by providing a broader dynamic range of blood velocity measurements in vivo.
DISCUSSION
Current methodologies for physiological imaging of PADs are sub optimal in that no single modality provides adequate spatial and temporal resolution to accurately assess all essential parameters, that is, vascular structure, arterial inflow, venous outflow and tissue per fusion. NIRII imaging technique simultaneously provides anatomical and hemodynamic information and surpasses the need to use multiple imaging modalities to obtain equivalent data, owing to reduced tissue scattering and deeper anatomical penetration of NIRII over shorter wavelengths. This is due to the inverse wavelength dependence (~λ -α , α = 0.22-1.68) 8 of photon scattering as they travel through subcutane ous tissue and skin (see ref. 8 and references therein). NIRII imaging compares favorably to microCT. Even with voxel dimensions of 40 µm, microCT was only capable of resolving vessels of ~100 µm, whereas NIRII could distinguish vessels approximately three times smaller, without obvious background signal from soft tissue. In terms of imaging depth, NIRII can achieve a penetration depth of 1-3 mm inside the hind limb in vivo without losing fidelity of the vessel structures, whereas microCT is able to reconstruct the wholebody structure in three dimensions owing to the unlimited penetration of Xrays. The time required for microCT (hours) as opposed to NIRII imaging (subseconds) also means longer anesthe sia time and high radiation doses, carrying risks of nephrotoxicity, anaphylaxis and tissue injury 32, 33 .
NIRII imaging has three salient advantages over ultrasonography. First, NIRII is able to image smaller vessels. Even with a high frequency (40 MHz) transducer, the diameter of mouse vessels could not be accurately determined with ultrasound, owing to poor spatial resolution and low contrast. Second, NIRII imaging is able to resolve both arterial and venous vessels anatomically and hemodynamically using PCA. Third, NIRII imaging can be used to acquire hemo dynamic data in conditions of reduced flow (for example, ischemic hind limb), below the detection limit of ultrasonography.
Given the many benefits of NIRII fluorescence imaging over other preclinical imaging modalities, this dualmodality method may be useful in a variety of cardiovascular models. Although our current work focused on assessing blood flow of small vessels, NIRII imag ing could be used to characterize in vivo the degree of stenosis or aneurysmal dilation of vessels. Because of its temporal resolution, it might also be useful for imaging dynamic changes in vessel diameter caused by active vasodilation or vasoconstriction. It is conceivable that NIRII fluorescence imaging with SWNTs and other novel NIRII fluorophores, including quantum dots 34, 35 and synthetic organic dyes 36 , could lead to many translational and clinical applications. 
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Preparation of water-soluble SWNT-IRDye-800 bioconjugate. The prepara tion of watersoluble and biocompatible SWNTs can be found in detail in a previously published paper with some modifications 37 . In general, raw high pressure carbon monoxide conversion SWNTs (Unidym) were suspended in 1 % wt/wt sodium deoxycholate aqueous solution by 1 h of bath sonication. This suspension was ultracentrifuged at 300,000g to remove the bundles and other large aggregates, the supernatant was retained and 0.75 mg ml −1 of DSPEmPEG (5 kDa) (1,2distearoylsnglycero3phosphoethanolamineN [methoxy(polyethyleneglycol, 5000)], Laysan Bio) along with 0.25 mg ml −1 of DSPEPEG (5 kDa)NH 2 (1,2distearoylsnglycero3phosphoethanolamine N[amino(polyethyleneglycol, 5000)], Sunbright) was added. The resulting suspension was sonicated briefly for 5 min and then dialyzed at pH 7.4 in a 3,500Da membrane (Fisher) with a minimum of six water changes and a mini mum of 2 h between water changes. To remove aggregates, the suspension was ultracentrifuged again for 1 h at 300,000g. This surfactantexchanged SWNT sample has lengths ranging from 100 nm up to 2.0 µm with the average length of ~500 nm. These aminofunctionalized SWNTs were further conjugated with IRDye800 (IRDye 800CW, LICOR) dye molecule according to the protocol that has been used in our group 38 . Briefly, an SWNT solution with amine functionality at 300 nM after removal of excess surfactant was mixed with 0.1 mM IRDye800 NHS ester (LICOR) in PBS at pH 7.4. The reaction was allowed to proceed for 1 h before purification to remove excess IRDye800 by filtration through 100kDa filters. The asmade SWNTIRDye800 conjugate solution was kept at 4 °C and away from light to avoid photobleaching of IRDye800 fluorescence.
UV-Vis-NIR absorption measurements.
The UVVisNIR absorption spec trum of the asmade SWNTIRDye800 bioconjugate was measured by a Cary 6000i UVVisNIR spectrophotometer, backgroundcorrected for contribution from water. The measured range was 500-820 nm.
NIR fluorescence spectroscopy of SWNT-IRDye-800 bioconjugate. The NIR fluorescence spectrum was taken using a homebuilt NIR spectroscopy setup. The excitation source was a 200W ozonefree mercury/xenon lamp (Oriel), which was dispersed by a monochromator (Oriel) to generate an excitation line with a central wavelength of 785 nm and a bandwidth of 15 nm. The excita tion light was allowed to pass through the solution sample in a 1mmpath cuvette (Starna Cells, Inc.), and the emission was collected in a transmission geometry. The excitation light was rejected using a 790nm longpass filter (Semrock) so that the fluorescence of both IRDye800 and SWNTs could be collected in the 790-1,500 nm emission range. The emitted light was directed into a spectrometer (Acton SP2300i) equipped with a liquidnitrogen-cooled InGaAs linear array detector (Princeton OMAV). Spectra were corrected postcollection to account for the sensitivity of the detector and extinction feature of the filter using the MATLAB software.
Determination of cytotoxicity of SWNTs. We determined the SWNT toxic ity in vitro by MTS assay using a CellTiter96 kit (Promega) on human dermal microvascular endothelial cells (Lonza). Approximately 5,000 cells were incu bated per well with 100 µl of EGM2MV growth medium (Lonza) and serially diluted SWNT solution (n = 3 for each concentration). The cells were kept at 37 °C in a humidified atmosphere containing 5% CO 2 for 24 h in the pres ence of SWNTs at different concentrations. Immediately before addition of 15 µl of CellTiter96, a colorimetric indicator of cell viability, the SWNTspiked medium was removed from each well plate and replaced with fresh medium. This prevented any interference in the absorbance readings from SWNTs. After 1 h, the color change was quantified using a plate reader and taking absorbance readings at 490 nm. Cell viability was plotted as a fraction of the absorbance of control wells incubated without SWNTs.
Mouse handling, surgery and injection. Sixweekold female athymic nude mice were obtained from Charles River. All mouse studies were approved by Stanford University's Administrative Panel on Laboratory Animal Care. Induction of unilateral hind limb ischemia was performed according to our previous studies 28, 30, 39 . Control, unsurgerized mice (n = 4) and mice with induced ischemia (n = 3) were used in the study. For the injection of nanotube solution, a 28gauge syringe needle was inserted into the lateral tail vein, allow ing for bolus injection with the room lights turned off during the first frames of imaging. All mice were initially anesthetized before imaging in a knockdown box with 2 l min −1 O 2 gas flow mixed with 3% isoflurane. A nose cone delivered 1.5 l min −1 O 2 gas and 3% isoflurane throughout imaging.
In vivo NIR fluorescence imaging with tunable magnifications. Mice were mounted on a heated stage in the supine position beneath the laser at 10 min after injection. NIR fluorescence images were collected using a 1,344 × 1,024 pixel silicon chargecoupled device camera (Hamamatsu) for collecting pho tons in NIRI and a liquidnitrogen-cooled, 320 × 256 pixel twodimensional InGaAs array (Princeton Instruments) for collecting photons in NIRII. A flip mirror was used to switch photon collection between the two cameras (Fig. 1d) .
The excitation light was provided by a 785nm diode laser (Renishaw) coupled to a 4.5mm focal length collimator (Thorlabs) and filtered by a 790nm band pass filter with a bandwidth of 10 nm (Thorlabs). The excitation power density at the imaging plane was 8 mW cm −2 , much lower than the safe exposure limit of 296 mW cm −2 at 785 nm determined by the International Commission on Nonionizing Radiation Protection 40 . The emitted light from the mouse was filtered through a 790nm longpass filter (Semrock) and an 850nm shortpass filter (Thorlabs) coupled with the silicon camera for the NIRI imaging window, or through a 900nm longpass filter (Thorlabs) and an 1100nm longpass filter (Thorlabs) coupled with the InGaAs camera for NIRII imaging. A lens set was used for obtaining tunable magnifications, ranging from ×1 to ×2.5 mag nification by changing the relative position of two NIR achromats (200 mm and 75 mm, Thorlabs) and from ×2.5 to ×7 magnification by changing the relative position of two other NIR achromats (150 mm and 200 mm, Thorlabs). A binning of 4 and an exposure time of 300 ms were used for the silicon camera (1,344 × 1,024 pixels) to capture images in the NIRI window, and a binning of 1 and an exposure time of 300 ms were used for the InGaAs camera (320 × 256 pixel) to capture images in the NIRII window. Different binnings were used to compensate the difference of array size of the two cameras.
Microscopic computed tomography for vascular imaging.
MicroCT scans were performed using a MicroCAT II microCT scanner (Siemens Preclinical Solutions) with the following parameters: Xray voltage 80 kVp, anode cur rent 50 mA and exposure time 2,000 ms per 576 frames through 360° rota tion. Mice were injected with the blood pool contrast agent Fenestra VC (50 mg ml −1 iodine, Advanced Research Technologies) intravenously into the lateral tail vein at 0.3 ml per 20 g body weight with a 28gauge needle. Mice (n = 2) were scanned 1 h after injection for 1 h total scan time. Three dimensional reconstruction was performed by COBRA 1.5 and visualized using Amira 5.4. Resulting voxel dimension was 40 µm. To determine the depth of femoral vessels and their collaterals, distance between the vessels and the edge of surrounding tissue was measured in reconstructed microCT images using ImageJ software.
Video-rate imaging in the NIR-II window. Videorate imaging was per formed on the same homebuilt imaging system as in the steadystate imaging case except that only an InGaAs camera was used for imaging in the NIRII window. The excitation light was provided by an 808nm diode laser (RMPC lasers) coupled to a 4.5mm focal length collimator (Thorlabs) and filtered by an 850nm shortpass filter and a 1,000nm shortpass filter (Thorlabs). The excitation power density at the imaging plane was 140 mW cm −2 , lower than the safe exposure limit 329 mW cm −2 at 808 nm 40 . The emitted light from the mouse was filtered through a 900nm longpass filter and a 1,100nm longpass filter (Thorlabs) so that the intensity of each pixel in the InGaAs twodimensional array represented light in the 1.1-1.7 µm range. A lens pair consisting of two achromats (200 mm and 75 mm, Thorlabs) was used focus the image onto the detector with a magnification of ×2.5. The InGaAs camera was set to expose continuously, and NIRII fluorescence images were acquired with LabVIEW software. The exposure time for all images shown in the movies was 100 ms. There was an 87.5ms overhead in the readout, leading to an average time of 187.5 ms between consecutive frames and a frame rate of 5.3 frames s −1 .
Dynamic contrast-enhanced imaging based on PCA. Dynamic contrast enhanced images were obtained in a similar fashion to previous work by the Hillman group 23 and our group 8 . The first 200 consecutive frames immediately after injection were loaded into an array using MATLAB software, and the builtin princomp function was used to perform PCA. During the mathematical process, faster flowing features showing up early in the movie are grouped in the negative fourth principal component, and slower flowing features showing up later in the movie are grouped in the negative second principal component. Therefore, negative pixels for the second principal component were colorcoded in blue to represent venous vessels and negative pixels for the fourth principal component were colorcoded in red to represent arterial vessels.
Quantification of blood velocity and flow based on NIR-II fluorescence.
Average region of interest (ROI) NIRII fluorescence intensity was computed using MATLAB software within a given arterial region of each frame, which was determined by PCA analysis as explained in the previous paragraph. Then the NIRII fluorescence intensity was plotted as a function of time to reveal the change over 4 min after intravenous injection. The intensity in the femoral artery increased rapidly within the first 5-10 s before residing. The NIRII intensity values were normalized against the maximum intensity within the ROI time traces to compensate for any differences in actual injection dose and relative fluorescence quantum yield. Linear fit was then performed on the rising edge of the normalized plot, and its slope (in % s −1 ) was translated into blood velocity in terms of cm s −1 by using the intensitytovelocity conver sion coefficient. Since the NIRII signal increase was averaged over the ROI, the velocity value was the mean blood flow velocity along the femoral artery. Blood flow (F) in ml min −1 (cm 3 min −1 ) was calculated on the basis of the blood velocity (V) in cm s −1 and the diameter of the vessel (d) in µm as follows:
Validation of intensity-to-velocity coefficient based on tubing flow model. A solution of SWNTs with known concentration was pumped by a syringe pump into catheter tubing with known diameter filled with purified water at a preset velocity (Supplementary Fig. 5k ). The following settings were used for the standard condition: SWNT concentration = 0.10 mg × ml −1 , SWNT fluorescence quantum yield (QY) ~2.5%, tubing diameter = 760 µm, tubing length within ROI (that is, ROI length) = 2.5 cm, fluid velocity = 1.4 cm s −1 and tubing length before ROI (that is, preROI length) = 8.5 cm. To screen the dependency of the coefficient on all these variables, the parameters were changed one at a time while keeping all others unchanged: SWNT concen tration changed to 0.025 mg ml −1 , SWNT fluorescence QY to 5.0%, tubing diameter to 380 µm, ROI length to 1.25 cm, fluid velocity to 0.14 cm s −1 and preROI length to 19.5 cm. Under each combination of settings, the NIRII fluorescence intensity within the selected ROI was plotted as a function of time from immediately after injection to the time when intensity plateaued. Then NIRII intensity values were normalized against the maximum inten sity (plateau intensity) within the ROI time traces. Linear fit was performed on the linear rise of each normalized plot to obtain a slope in % s −1 . The intensity increase rate (slope) in % s −1 was then used to divide the velocity in cm s −1 to obtain the intensitytovelocity conversion coefficient in cm % −1 . For numerical simulation, a tubing linear flow model with axial mixing was adapted from a previous publication 29 . A sigmoidal function with time and velocity dependence was used to simulate NIRII intensity distribution at the flow front upon mixing using MATLAB software. The flow front function F(x,v,t) was given analytically by the equation Fig. 5l-r) . The linear rise region was fit to a linear equation, and the slope was used to divide the velocity, giving the intensitytovelocity conversion coefficient
( ) = ∂ ∂ norm Ultrasound for quantifying blood flow in femoral artery. Ultrasound mea surements were performed using a linear realtime transducer (40 MHz) con nected to a Vevo 2100 ultrasound system (VisualSonics). The femoral artery was identified employing Duplexultrasonography (BMode and power Doppler). Flow velocity profiles were recorded by pwDoppler imaging. Velocitytime integrals (VTI) and cardiac cycle length (CL) were measured using the Vevo 2100 device software. Arterial diameter (d) was known for each mouse from previous NIRII imaging. Femoral flow (F) was calculated as: F = stroke volume (SV) × heart rate (HF) = arterial crosssectional area (CSA) × VTI × HF = π × (d/2) 2 × VTI × 60,000 / CL and averaged from three cardiac cycles.
